Literature DB >> 3013156

Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver.

N J Pyne, M E Cooper, M D Houslay.   

Abstract

Two enzymes displaying cyclic GMP-stimulated cyclic AMP phosphodiesterase activity were purified from rat liver to apparent homogeneity: a 'particulate enzyme' found as an integral membrane protein associated with the plasma membrane, and a 'soluble' enzyme found in the cytosol. The physical properties of these enzymes were very similar, being dimers of Mr 134,000, composed in each instance of two subunits of Mr = 66,000-67,000. Both enzymes showed similar kinetics for cyclic AMP hydrolysis. They are both high-affinity enzymes, with kinetic constants for the particulate enzyme of Km = 34 microM and Vmax. = 4.0 units/mg of protein and for the cytosolic enzyme Km = 40 microM and Vmax. = 4.8 units/mg of protein. In both instances hydrolysis of cyclic AMP appeared to show apparent positive co-operativity, with Hill coefficients (happ.) of 1.5 and 1.6 for the particulate and cytosolic enzymes respectively. However, in the presence of 2 microM-cyclic GMP, the hydrolysis of cyclic AMP obeyed Michaelis kinetics (happ. = 1) for both enzymes. The addition of micromolar concentrations of cyclic GMP had little effect on the Vmax. for cyclic AMP hydrolysis, but lowered the Km for cyclic AMP hydrolysis to around 20 microM in both cases. However, at low cyclic AMP substrate concentrations, cyclic GMP was a more potent activator of the particulate enzyme than was the soluble enzyme. The activity of these enzymes could be selectively inhibited by cis-16-palmitoleic acid and by arachidonic acid. In each instance, however, the hydrolysis of cyclic AMP became markedly more sensitive to such inhibition when low concentrations of cyclic GMP were present. Tryptic peptide maps of iodinated preparations of these two purified enzyme species showed that there was considerable homology between these two enzyme forms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013156      PMCID: PMC1146569          DOI: 10.1042/bj2340325

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  A micro biuret method for protein determination; determination of total protein in cerebrospinal fluid.

Authors:  J GOA
Journal:  Scand J Clin Lab Invest       Date:  1953       Impact factor: 1.713

2.  The role of cyclic GMP in the regulation of cyclic AMP hydrolysis.

Authors:  W L Terasaki; M M Appleman
Journal:  Metabolism       Date:  1975-03       Impact factor: 8.694

3.  Hydrodynamic properties of the beta-adrenergic receptor and adenylate cyclase from wild type and varient S49 lymphoma cells.

Authors:  T Haga; K Haga; A G Gilman
Journal:  J Biol Chem       Date:  1977-08-25       Impact factor: 5.157

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  The nature of the electrophoretically separable multiple forms of rat liver monoamine oxidase.

Authors:  M D Houslay; K F Tipton
Journal:  Biochem J       Date:  1973-09       Impact factor: 3.857

6.  Separate phosphodiesterases for the hydrolysis of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in rat liver.

Authors:  T R Russell; W L Terasaki; M M Appleman
Journal:  J Biol Chem       Date:  1973-02-25       Impact factor: 5.157

7.  Multiple cyclic nucleotide phosphodiesterase activities from rat brain.

Authors:  W J Thompson; M M Appleman
Journal:  Biochemistry       Date:  1971-01-19       Impact factor: 3.162

8.  The glucagon receptor of rat liver plasma membrane can couple to adenylate cyclase without activating it.

Authors:  M D Houslay; J C Metcalfe; G B Warren; T R Hesketh; G A Smith
Journal:  Biochim Biophys Acta       Date:  1976-06-17

9.  Cyclic nucleotide hydrolysis in the thyroid gland. General properties and key role in the interrelations between concentrations of adenosine 3':5'-monophosphate and guanosine 3':5'-monophosphate.

Authors:  C Erneux; J Van Sande; J E Dumont; J M Boeynaems
Journal:  Eur J Biochem       Date:  1977-01-03

10.  Substrate and effector specificity of a guanosine 3':5'-monophosphate phosphodiesterase from rat liver.

Authors:  J Moss; V C Manganiello; M Vaughan
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

View more
  18 in total

1.  Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.

Authors:  Y Shakur; J G Pryde; M D Houslay
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

2.  Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated 'dense-vesicle' and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat.

Authors:  N J Pyne; N Anderson; B E Lavan; G Milligan; H G Nimmo; M D Houslay
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

Review 3.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

4.  Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected].

Authors:  Y M Horton; M Sullivan; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

5.  Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase.

Authors:  G Scotland; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

6.  The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity.

Authors:  N J Pyne; M E Cooper; M D Houslay
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

7.  Subcellular localization and hormone sensitivity of adipocyte cyclic AMP phosphodiesterase.

Authors:  N G Anderson; E Kilgour; M D Houslay
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

8.  Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.

Authors:  Y Shakur; M Wilson; L Pooley; M Lobban; S L Griffiths; A M Campbell; J Beattie; C Daly; M D Houslay
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

9.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

10.  Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes.

Authors:  Corina Russwurm; Georg Zoidl; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.